Hers vs Noom: Behavioral App or Clinical GLP-1 Telehealth

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Some weight-management brands sell a prescription; others sell a behavior-change system and treat medication as an add-on. That philosophical split is the real story behind Hers versus Noom. This PlexusDx Education Hub review compares the two models and then turns to a biological factor sitting beneath both. Browse all Peptides & GLP-1 education.

Independence statement: PlexusDx has no commercial relationship with Hers, Noom, or their parent companies. No affiliate links, sponsorships, or referral fees influenced this review.

Hers and Noom both appear in searches for online GLP-1 help, yet they were built around different ideas of what changes weight. One leads with clinical telehealth and dispensing; the other leads with psychology, tracking, and coaching, layering medication on top. The sections below examine each philosophy, where the medicine fits, how cost is structured, and the inherited variable neither model measures. Details are current as of April 2026.

The Hers model: clinical telehealth first

Hers, under Hims & Hers Health, is organized around subscription telehealth. A virtual evaluation leads to a licensed clinician's review and, where appropriate, a prescription for an FDA-approved brand GLP-1 or a compounded semaglutide or tirzepatide from a licensed compounding pharmacy. The current structure is documented at Hers's official website.

The Noom model: behavior change with a medication option

Noom built its reputation on an app-based subscription centered on habit tracking, psychology-informed coaching, and daily logging, later adding a medication pathway. Its program tiers, medication access, and pricing evolve, so the authoritative reference is Noom's official website at the time you evaluate it.

Coaching versus prescribing: where they diverge

The core distinction is emphasis. A behavior-first program invests in engagement, lessons, and accountability, with medication as one tool among several. A telehealth-first program invests in the clinical encounter and dispensing, with lifestyle guidance as support. Neither emphasis is inherently superior; they suit different people. Someone who wants structured coaching may value Noom's design, while someone focused on obtaining and managing a prescription may prefer a clinical-telehealth flow.

The compound is the same regardless of the wrapper

Wrapped in an app or delivered through a clinic, the medication class does not change. GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, plus the GIP/GLP-1 dual agonist tirzepatide, act on appetite regulation, satiety, and gastric emptying. Coaching can support adherence and habits, but it does not alter the pharmacology. What separates Hers from Noom is the surrounding program, not the biology of the drug itself.

How each program prices its offer

Pricing reflects the model. Behavior-first subscriptions and clinical-telehealth programs assemble cost differently, but as of April 2026 monthly totals across GLP-1 telehealth commonly range from roughly $200 to $700 or more, driven by the compound, plan length, and any coaching or membership layer. Because a coaching subscription and a medication fee may be billed separately, confirm the full stacked cost on each brand's own site before deciding.

What the research supports

The medications carry a strong evidence base. Semaglutide was tested for weight management in STEP (New England Journal of Medicine, 2021); tirzepatide in SURMOUNT (NEJM, 2022); and tirzepatide for obstructive sleep apnea in SURMOUNT-OSA (NEJM, 2024). Doses, endpoints, and study populations vary across these trials, and averages never predict a single person's result.

The variable no coach can log

A tracking app can record your meals and steps, but it cannot read the inherited biology underneath them. A variant in TCF7L2, tied to glucose homeostasis and GLP-1 secretion, along with FTO, GLP1R (the receptor these compounds target), and MC4R (central to satiety), maps your baseline metabolic terrain. These pathway-level markers do not predict response to any specific compound, but they describe the biology behind the numbers a coach helps you track.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before a protocol, the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2, so behavior change and medication both start from a clearer picture. Test before you invest.

Not affiliated: PlexusDx has no relationship with Hers or Noom and reviewed both independently.

Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers or Noom and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Explore the Weight Management Protocols or begin with the Precision Peptide Genetic Test.

Frequently Asked Questions

Is Noom a medication program or a coaching app?

Noom began as a behavior-change app centered on coaching and habit tracking, then added a medication pathway. Depending on the tier you choose, you may pay for coaching, medication, or both. Because the structure varies, confirm exactly what each Noom plan includes on the brand's own site before enrolling.

Does coaching improve GLP-1 results compared with telehealth alone?

Coaching and habit tracking can support adherence and lifestyle change, which many people find helpful alongside medication. They do not alter the drug's mechanism, however. Whether Noom's coaching emphasis or a clinical-telehealth flow suits you depends on how much structure and accountability you personally want.

Where does the Precision Peptide Genetic Test fit with coaching?

The test is not a coaching or tracking tool and does not predict drug response. It maps pathway-level variants such as FTO and MC4R, and TCF7L2 that describe your baseline metabolic biology, offering context that complements any behavior-change program regardless of which brand you use.

How does PlexusDx compare with an app-first model?

PlexusDx centers biology rather than behavioral coaching. It provides semaglutide and tirzepatide through its Weight Management Protocols and adds the Precision Peptide Genetic Test for upstream context, mapping FTO, MC4R, a genetic layer that an app-first program like Noom does not include.

Keep exploring the Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.